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OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Is 
spironolactone an effective method for reducing lesion count in individuals with acne vulgaris?” 
STUDY DESIGN: A systematic review of three English language studies published after 2009 in 
peer-reviewed journals, including two randomized, controlled trials and one retrospective cohort 
study. 
DATA SOURCES: Two randomized, controlled trials and one retrospective cohort study that 
evaluated spironolactone as a treatment for acne vulgaris were found using PubMed. 
OUTCOMES MEASURED: Reductions in total lesion counts (TLC). 
RESULTS: All three studies supported the efficacy of spironolactone in reducing lesion counts 
in individuals with acne vulgaris. Kelidari et al. (Colloid Surface B. 2016;146:47-53. 
doi:10.1016/j.colsurfb.2016.05.042) demonstrated a significant reduction in total lesion counts in 
both groups treated with spironolactone between baseline and week 8, with a p-value < 0.001. 
Afzali et al. (J Dermatol Treat. 2012;23(1):21-25. doi:10.3109/09546634.2010.488260) showed 
a significant difference between the case and control groups with p-value = 0.007, reflecting the 
efficacy of spironolactone in reducing total lesion count. The retrospective cohort study by Isvy-
Joubert et al. (Eur J Dermatol. 2017;27(4):393-398. doi:10.1684/ejd.2017.3062) exhibited that 
71% of patients treated with spironolactone for acne vulgaris experienced reduction in lesion 
counts. 
CONCLUSIONS: The results of the randomized, controlled trials and retrospective cohort study 
indicate that spironolactone is effective in reducing lesion counts in individuals with acne.  
KEY WORDS: Acne, Spironolactone, Aldactone. 
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INTRODUCTION 
Acne vulgaris is a very common dermatologic condition affecting individuals of all ages. 
It is a disease process of the pilosebaceous gland, characterized by hyperseborrhea, 
noninflammatory lesions (comedones), and inflammatory lesions, which include papules, 
pustules, nodules, and cysts. The chronic nature of acne vulgaris poses physical, psychological, 
and economic implications, both to the individual suffering and society at large. 
Acne vulgaris is the most common skin condition diagnosed by dermatologists and is 
frequently encountered in other areas of medicine such as pediatrics and primary care.1 Extensive 
data reflect the universality of acne, revealing that 40-50 million people in the U.S. and 80% of 
individuals between the ages of 11 and 30 suffer with acne.2,3 In addition to being widespread in 
society, acne often persists into late adolescence and adulthood: 64% and 42% of individuals 
have unremitting acne into their 20s and 30s, respectively.1 Furthermore, the prevalence of both 
early onset and late adult acne is increasing, likely due to earlier onset of puberty.2,4 
This condition has grave socioeconomic and psychological consequences. Severe acne is 
associated with rising rates of anxiety, suicidal ideation and unemployment.2,3 A particular study 
concluded that acne patients were two to three times more likely to experience depression, 
reporting an 8.8% prevalence of clinically diagnosed depression in the sample population of acne 
patients.3 It is estimated that over 2 billion dollars and over 5 million health care visits are 
dedicated to the management of acne each year in the U.S.1  
The pathophysiology of acne is complex and multifactorial, involving both genetic and 
environmental factors. Acne is the result of the interactions between bacteria, inflammation, and 
a rise in hormones during puberty.1,5 This surge of androgens provokes abnormal differentiation 
of follicular cells, development of hyperkeratotic plugs, and increased sebum production, 
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followed by the overgrowth of the bacteria Propionibacterium acnes (P. acnes).1 It is well 
known that acne is genetically inherited, occurring more commonly and more severely in those 
who have first-degree relatives with a history of acne.1,2 While studies link dairy intake and 
cigarettes with increased acne risk, they fail to identify the highly debated roles of UV light and 
chocolate.1  
Treatment regimens are individualized to each patient, usually consisting of some 
combination of topical or oral antimicrobials, topical retinoids, salicylic acid, benzoyl peroxide, 
oral contraceptives, and isotretinoin in severe and refractory cases.1 Treatment should also 
incorporate patient counseling in proper hygiene and recommendation of skincare products, such 
as cleansers, moisturizers, and makeup.1 
Although its specific role in acne remains unclear, P. acnes is often the target of acne 
treatment, through the use of antimicrobials such as sulfonamides, macrolides, tetracyclines, and 
dapsone.1 However, the development of bacterial resistance via biofilms threatens the efficacy of 
this treatment option.2 Although highly effective in reducing sebum production and treating acne, 
isotretinoin poses the risks of teratogenicity, altered mood, and hypertriglyceridemia.2 These 
issues with current treatment options propose a need for further research into alternative acne 
treatments. 
The aforementioned treatment options are supported only by limited scientific evidence 
and often require numerous adjustments to achieve success.2 Several research studies have 
demonstrated the efficacy of spironolactone, which targets the excess of androgens associated 
with acne by competitively inhibiting dihydrotestosterone at the androgen receptor.4 This paper 
evaluates two randomized control trials (RCT) and one retrospective cohort study evaluating the 
efficacy of spironolactone as a method for reducing lesion counts in patients with acne vulgaris. 
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OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not “Is 
spironolactone an effective method for reducing lesion count in individuals with acne vulgaris?” 
METHODS 
 The three studies in this review were researched through PubMed using keywords 
“acne,” “spironolactone,” and “Aldactone.” All articles were published in English in peer-
reviewed journals after 2009. Articles were selected by the author based on relevance to the 
clinical question and patient-centered outcomes, including studies published after 2009 with a 
primary research design. Studies published prior to 2009 were excluded from this systematic 
review. Statistics utilized in the three studies to evaluate outcomes include p-values and mean 
change from baseline. Table 1 illustrates the demographics and characteristics of each study. 
Two double-blind, randomized controlled trials and one retrospective cohort study were 
included in this systematic review. Selection criteria included population, intervention, 
comparison, and patient-centered outcomes measured. The population studied consisted of both 
male and female patients over the age of 8 years with acne vulgaris. The intervention studied was 
spironolactone, either oral or topical preparation, compared to the control group who received 
either placebo or a different dose of spironolactone. Isvy-Joubert et al. investigated outcomes in a 
sample of women treated with low dose spironolactone (< 150 mg/day) for six months through a 
retrospective cohort study.4 The subjects of Kelidari et al. were treated for 8 weeks with either 10 
mg spironolactone in a nanostructured lipid carrier (SP-NLC 1%) or 50 mg spironolactone in an 
alcohol gel (SP-ALC 5%).5 The participants in the study conducted by Afzali et al. either 
received topical 5% spironolactone gel or a placebo gel, applied twice a day for 6 weeks.6 The 
efficacy of spironolactone was measured based on the reduction in total lesion counts.   
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Table 1. Demographics & Characteristics of included studies 
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OUTCOMES MEASURED 
 The three studies measured the outcome of the intervention based on the total lesion 
counts, which is the summary of comedones, papules, and pustules.6 Kelidari et al. assessed 
changes in facial lesion counts based on number, type, and distribution at 0, 2, 4, and 8 weeks.5 
Afzali et al. also evaluated changes in total lesion counts at 2-week intervals up to 6 weeks.6 
Both Kelidari et al. and Afzali et al. calculated change in lesion counts from baseline in order to 
evaluate the efficacy of spironolactone, using a p-value < 0.05 to establish clinical 
significance.5,6 
Isvy-Joubert et al. examined data of women treated with spironolactone between January 
2010 and 2015, measuring outcomes based on the lesion count of superficial inflammatory 
lesions (papules and pustules) and retentional lesions (open and closed comedones) on the face, 
back, neck, and breast after six months of treatment.4 Good clinical response was defined as £ 2 
superficial inflammatory lesions on the face and £ 5 retentional lesions after six months of 
treatment.4  
RESULTS 
 This systematic review analyzed two randomized, double-blind, controlled trials and one 
retrospective cohort study to determine the efficacy of spironolactone in reducing lesion counts 
in individuals with acne vulgaris. Both Kelidari et al. and Afzali et al. studied patients of all ages 
with mild to moderate acne, excluding patients who were pregnant, lactating, or planning to 
become pregnant.5,6 Kelidari et al. excluded patients suffering from any other skin disease that 
might interfere with the biweekly skin assessments completed to measure the effect of 
spironolactone on acne.5 Afzali et al. excluded individuals who had taken antibiotics or hormone 
medications in the last 3 months, as these may have had an impact on their acne.6 Isvy-Joubert et 
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al. studied adult women over the age of 20 with mild to severe acne, excluding those with 
hidradenitis suppurativa or rosacea, as they may have been treated with anti-androgens for those 
conditions.4  
 Isvy-Joubert et al. analyzed the data of 70 adult women aged 20-34 years with acne who 
were treated with low dose (<150 mg/day) spironolactone between January 2010 and 2015.4 At 
the initiation of spironolactone, the participants’ acne was classified by the number of 
inflammatory lesions: 76% had mild acne (<10 lesions), 17% had moderate acne (10-20 lesions), 
and 7% had severe acne (>20 lesions).4 Lesion counts were assessed at initial prescription of 
spironolactone and at routine follow-up visits at 3-4 months, 6-8 months, and then every 6 
months.4 Remission was characterized by the presence of  £ 2 superficial inflammatory lesions 
and £ 5 retentional lesions after six months of treatment.4 Based on the collected data, a 
remission analysis was conducted on 52 women to evaluate the efficacy of spironolactone in 
reducing their lesion counts.4 Of these women, 71% (n=47) were characterized as successful 
treatments based on the remission criteria previously mentioned.4 
Table 2. Mean lesion counts from baseline to 6 months.4 
 Baseline 6 Months % Reduction 
Facial Inflammatory 
Superficial Lesions 
8 2.5 68.75% 
Facial Retentional 
Lesions 
8.5 2.75 67.65% 
  
Kelidari et al. conducted a randomized, double-blind, controlled trial on 76 patients aged 
8-38 years with mild to moderate acne.5 Group A received 10 mg spironolactone-loaded 
nanostructured lipid carrier gel (SP-NLC 1%), while group B received 50 mg spironolactone 
loaded alcohol gel (SP-ALC 5%).5 Both groups were instructed to wash their face, apply a 2 cm 
amount of the gel each morning and evening, then massage for two minutes, and finally wash the 
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gel off after 2-3 hours.5 Facial lesion counts were assessed based on number, type, and 
distribution at 0, 2, 4 and 8 weeks.5 In total, 16 patients withdrew from the study due to personal 
reasons or allergies.5 There was a statistically significant decrease in total lesion counts between 
baseline and week 8 for both groups A and B, with p < 0.001.5 The administration of SP-NLC 
1% in group A yielded a 47.18% reduction in TLC with p-value = 0.003.5 For group B, who 
received SP-ALC 5%, there was a 43.77% reduction in TLC with p-value = 0.022.5 These data 
are illustrated in further detail in Table 3 below. 
Table 3. Mean change in TLC from baseline to 8 weeks.5 
 Mean TLC at Baseline (± SD) 
Mean TLC at 




in TLC p-values 
Group A 37.165 ± 9.28 19.63 ± 6.36 17.54 47.18% P = 0.003 
Group B 32.60 ± 9.32 18.33 ± 5.56 14.27 43.77% P = 0.022 
 
 
Afzali et al. conducted a randomized, double-blind, placebo controlled trial on 78 patients 
aged 11-30 years with mild to moderate acne.6 The case group received a topical gel containing 
5% spironolactone, while the control group received a topical placebo gel of similar formulation 
without spironolactone.6 Both groups were instructed to apply the gel twice per day and wash off 
after 2-3 hours.6 Total lesion counts were assessed every 2 weeks up to 6 weeks, based on 
number, type, and distribution.6 There was a statistically significant difference in total lesion 
counts between the two groups at week 6, with p-value = 0.007.6 There was a 71% reduction in 
the TLC from baseline in the case group, with a p-value < 0.01.6 The control group experienced a 
36.02% reduction in the TLC from baseline, with a p-value < 0.01.6 These results are displayed 
below in Table 4 in more detail. 
Table 4. Mean change in TLC from baseline to 6 weeks.6 
 Mean TLC at Baseline (±SD) 
Mean TLC at 




in TLC p-values 
Case Group 17.5 ± 11.4 5.1 ± 4.7 12.4 71.0% P < 0.01 
Control Group 15.7 ± 12.9 10.0 ± 6.5 5.7 36.02% P < 0.01 
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In the retrospective cohort study conducted by Isvy-Joubert et al., 24% of patients 
reported treatment-related side effects, including menstrual irregularities, cramps, and low blood 
pressure.4 While Kelidari et al. reported that there were no serious adverse events related to 
treatment with spironolactone, they documented complaints of dryness and itchiness from 
participants.5 Among the control group in Afzali et al., 11.1% of patients complained of 
pigmentation at the treatment site and 8.3% showed scaling, while none of the patients in the 
case group reported either of these side effects.6 Additionally, 9.1% of the case group and 13.9% 
of the control group developed erythema during this trial.6 
DISCUSSION 
 Spironolactone, known by the brand name Aldactone, is approved by the FDA for use in 
primary aldosteronism, congestive heart failure, cirrhosis of the liver, nephrotic syndrome, 
essential hypertension, and hypokalemia.7 Off-label uses include acne vulgaris, hirsutism, and 
hormone therapy for transgender females.8 Although spironolactone has been increasingly used 
in the treatment of acne for the past 30 years, the limited number of existing controlled trials as 
well as the small sample size of published studies provide insufficient data supporting its clinical 
efficacy.9,10 Despite this, the American Academy of Dermatology states: “the work group 
supports the use of spironolactone in the management of acne in select women.”10 Furthermore, 
the severe side effects associated with isotretinoin and the growing development of antibiotic 
resistance justify the urgent need for further research of alternative acne treatments.9  
The reluctance of the FDA to approve spironolactone for the treatment of acne is 
warranted by the black box warning, which states “Aldactone has been shown to be a tumorigen 
in chronic toxicity studies in rats. Aldactone should be used only in those conditions described 
under Indications and Usage. Unnecessary use of this drug should be avoided.” 7 However, 
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researchers question the authority and validity of this warning, arguing that the rats in the studies 
were given a dose of spironolactone 100-150 times greater than doses given in clinical practice 
to treat individuals for acne.9 Additionally, a recent retrospective cohort study published 
confounding evidence, establishing that there was no association found between spironolactone 
and breast cancer among the 1.29 million women who participated in the study.10 These findings 
are crucial in the recognition of spironolactone as a viable and safe treatment option for acne 
vulgaris.  
 The apprehension associated with spironolactone due to the black box warning is only 
intensified by the potential teratogenicity and contraindications of this drug. Spironolactone is 
contraindicated for patients with hyperkalemia, acute renal insufficiency, severe renal 
impairment, Addison disease, anuria, pregnancy, breastfeeding, and concurrent use of eplerenone 
or heparin.7,8 Spironolactone is pregnancy category C, which indicates that despite the existence 
of animal studies showing adverse effects on the fetus, the potential benefit of spironolactone 
may warrant use in pregnant women.7 Animal reproduction studies yielded variable results: no 
teratogenicity or embryotoxicity was found in mice, while feminization of male fetuses was seen 
in rats.7 While there is also possibility of sex differentiation of male embryos in humans due to 
anti-androgenic activity, the FDA maintains that spironolactone may be used in pregnant women 
if the benefit outweighs the risk to the fetus.7 
The studies included in this systemic review demonstrated the efficacy of spironolactone 
in reducing total lesion counts in acne vulgaris, as well as the relative safety of this treatment 
option. Isvy-Joubert et al. concluded that 71% of patients treated with spironolactone for acne 
vulgaris displayed a good clinical response based on established criteria.4 Kelidari et al. 
exhibited a statistically significant reduction in total lesion counts in both groups treated with 
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spironolactone compared to baseline.5 The case group in the study conducted by Afzali et al. 
displayed a significant improvement in total lesion count compared to the control group.6 Isvy-
Joubert et al. focuses on the population of adult women who experience hormone-related acne 
that is persistent through adulthood and flares up prior to menstruation, attributing the efficacy of 
spironolactone in these women to the hypersensitivity of their androgen receptors.4 However, 
research by Barbieri et al. emphasizes the effectiveness of spironolactone in women of all ages, 
while Afzali et al. and Kelidari et al. demonstrate the value of spironolactone in both males and 
females.5,6,9 Isvy-Joubert et al. published data identifying the number of inflammatory superficial 
lesions and the concurrent usage of third and fourth generation oral contraceptives as positive 
predictors of successful treatment response with spironolactone.4 This new information may aid 
clinicians when selecting candidates suitable for spironolactone therapy in the future. 
The limited inventory of recent research on the treatment of acne with spironolactone 
made the compilation of this systematic review slightly challenging. The lack of randomization, 
blinding, and control group in the retrospective cohort study conducted by Isvy-Joubert partially 
discounts the credibility of the research, establishing only associations rather than cause and 
effect. Although Kelidari et al. utilized double-blind procedures, the limited sample size of 76 
participants and the considerable dropout rate of 16 participants reduce the overall 
generalizability of this study.5 Another factor that may have influenced the outcome of the study 
was the permitted use of non-medicated cosmetics throughout the trial, which may have affected 
the participants’ skin condition.5 There was also reason to question the generalizability of Afzali 
et al., with a sample size of only 78, a short duration of 6 weeks, and 16 patients lost to follow 
up.6 Additionally, the alcohol content of both the placebo and spironolactone gel formulations 
administered to participants of this trial should be acknowledged as a possible contributor to the 
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reduced lesion counts.6 Although these studies have limited generalizability due to low sample 
sizes and high dropout rates, the research is clinically relevant due to the diverse populations 
studied, including both females and males ranging in age from 8 to 52 years. Isvy-Joubert et al. 
identified multiple factors that may predict clinical response to spironolactone, such as 
concurrent use of oral contraceptives and number of inflammatory lesions at baseline.4 
Additionally, this research supports the efficacy of spironolactone as an alternative treatment 
option, specifically for patients who have failed other treatments such as antimicrobials, zinc, 
and isotretinoin.4 
CONCLUSION 
The three studies analyzed in this systematic review confirm that spironolactone is an 
effective method for reducing lesion counts in individuals with acne vulgaris. Despite small 
sample sizes and large dropout rates, the significant evidence established by Kelidari, Afzali, and 
Isvy-Joubert opens a window of opportunity to initiate further research into the approval and use 
of spironolactone as a first line agent for acne vulgaris. Future research is needed in the form of 
long-term, randomized, controlled trials studying the effects of both oral and topical 
spironolactone. Populations should consist of larger sample sizes including both females and 
males of all ages. With additional research into safety and efficacy, spironolactone could 
possibly replace oral antibiotics, which remain the most common systemic agent prescribed for 
acne treatment despite negative effects on the gut microbiome and the growing concern of 
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